FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549
vvasiiiiiqtoii,	D.C.	20343

STATEMENT	OF	CHANGES	IN BENEFICIA	L OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-028							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Amoroso Michael  (Last) (First) (Middle)  C/O PRECISION BIOSCIENCES, INC.  302 E. PETTIGREW STREET, SUITE A-100  (Street)  DURHAM NC 27701					2. Issuer Name and Ticker or Trading Symbol PRECISION BIOSCIENCES INC [ DTIL ]  3. Date of Earliest Transaction (Month/Day/Year)  03/21/2022  4. If Amendment, Date of Original Filed (Month/Day/Year)						Che X A 6. Inc Line)	S. Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner     X Officer (give title Other (specify below)     President and CEO      6. Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person				
(City)	(S		(Zip)	orivet	ivo C	ouritie:	- A -	auirod D	icnocod (	of or Bo	noficially	Ownod				
2. Transa Date (Month/E				rivativ g., put	Execution Date, if any (Month/Day/Year)    Execution Date, if any (Month/Day/Year)   Transaction Code (Instr. 8)   Disposed Of (D) (Instr. 3, 2)			ed (A) or ttr. 3, 4 and 5  r Price  eficially ( urities)  d Amount ies g	5. Amount of 6 Securities F Beneficially (I Owned Following Reported Transaction(s) (Instr. 3 and 4)		Ownersl Form:	Beneficial				
(Instr. 3)	Price of Derivative Security	,	(Month/Day/Year)	8)	Acquired (A) Derivative (Instr. 3 ar of (D) (Instr. 3, 4 and 5)			(Instr. 5)	Beneficially Owned Following Reported	or Indire (I) (Instr.	ct (Instr. 4)					
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction (Instr. 4)	n(s)		
Employee Stock Option (Right to Buy)	\$3.05	03/21/2022		A		482,771		(1)	03/20/2032	Common Stock	482,771	\$0.00	482,771	. D		
Restricted Stock Units	(2)	03/21/2022		A		307,544		(3)	(3)	Common Stock	307,544	\$0.00	307,544	D		

## **Explanation of Responses:**

- 1. The option vests as to 25% of the underlying shares on March 21, 2023 and thereafter in twelve substantially equal installments at the end of each three-month period over the 36 months following such date, subject to the Reporting Person's continued service to the Company through the applicable vesting dates.
- 2. The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of the Company's Common Stock.
- 3. The RSUs shall vest in three substantially equal annual installments beginning on March 21, 2023, subject to the Reporting Person's continued service to the Company through the applicable vesting dates.

## Remarks:

/s/ Dario Scimeca, Attorney-in-Fact for Michael Amoroso

03/23/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.